Applied Therapeutics Urges Shareholders to Tender Shares as Cycle Group Acquisition Offer Extended

Reuters01-29

<a href="https://laohu8.com/S/AMAT">Applied</a> <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Urges Shareholders to Tender Shares as Cycle Group Acquisition Offer Extended

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, has provided an update on its pending acquisition by Cycle Group Holdings Limited, a UK-based company specializing in rare genetic conditions. The company confirmed that the offer period for Cycle's subsidiary, AT2B, Inc., to purchase Applied Therapeutics shares has been extended. Applied Therapeutics reiterated that, after considering alternative strategic options and not receiving any competing proposals since the agreement was signed on December 11, 2025, the transaction with Cycle remains the best available option for maximizing stockholder value. The company also noted that if the transaction is not completed, the share price could decline, especially if current trading levels reflect expectations that the deal will close. This update was disclosed in a letter to stockholders from Applied Therapeutics.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Applied Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9645308-en) on January 29, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2607508084?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-29 21:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2607508084","market":"fut","top_or_hot":-1,"title":"Applied Therapeutics Urges Shareholders to Tender Shares as Cycle Group Acquisition Offer Extended","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/AMAT\">Applied</a> <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Urges Shareholders to Tender Shares as Cycle Group Acquisition Offer Extended\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, has provided an update on its pending acquisition by Cycle Group Holdings Limited, a UK-based company specializing in rare genetic conditions. The company confirmed that the offer period for Cycle's subsidiary, AT2B, Inc., to purchase Applied Therapeutics shares has been extended. Applied Therapeutics reiterated that, after considering alternative strategic options and not receiving any competing proposals since the agreement was signed on December 11, 2025, the transaction with Cycle remains the best available option for maximizing stockholder value. The company also noted that if the transaction is not completed, the share price could decline, especially if current trading levels reflect expectations that the deal will close. This update was disclosed in a letter to stockholders from Applied Therapeutics.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/APLT\">Applied Therapeutics Inc.</a> published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9645308-en) on January 29, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Applied Therapeutics Urges Shareholders to Tender Shares as Cycle Group Acquisition Offer Extended</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApplied Therapeutics Urges Shareholders to Tender Shares as Cycle Group Acquisition Offer Extended\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-29 21:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/AMAT\">Applied</a> <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Urges Shareholders to Tender Shares as Cycle Group Acquisition Offer Extended\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, has provided an update on its pending acquisition by Cycle Group Holdings Limited, a UK-based company specializing in rare genetic conditions. The company confirmed that the offer period for Cycle's subsidiary, AT2B, Inc., to purchase Applied Therapeutics shares has been extended. Applied Therapeutics reiterated that, after considering alternative strategic options and not receiving any competing proposals since the agreement was signed on December 11, 2025, the transaction with Cycle remains the best available option for maximizing stockholder value. The company also noted that if the transaction is not completed, the share price could decline, especially if current trading levels reflect expectations that the deal will close. This update was disclosed in a letter to stockholders from Applied Therapeutics.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/APLT\">Applied Therapeutics Inc.</a> published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9645308-en) on January 29, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"APLT","symbol_name":"Applied Therapeutics Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nNDL6ZdtTJ:1","article_id":"2607508084","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2607508084","pubTimestamp":1769692527,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, has provided an update on its pending acquisition by Cycle Group Holdings Limited, a UK-based company specializing in rare genetic conditions. The company confirmed that the offer period for Cycle's subsidiary, AT2B, Inc., to purchase Applied Therapeutics shares has been extended. Applied Therapeutics reiterated that, after considering alternative strategic options and not receiving any competing proposals since the agreement was signed on December 11, 2025, the transaction with Cycle remains the best available option for maximizing stockholder value. The company also noted that if the transaction is not completed, the share price could decline, especially if current trading levels reflect expectations that the deal will close. This update was disclosed in a letter to stockholders from Applied Therapeutics.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. Whil","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"APLT":"Applied Therapeutics Inc.","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","NDAQ":"纳斯达克OMX交易所","BK4588":"碎股","BK4112":"金融交易所和数据","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H"},"translate_title":"随着Cycle Group收购要约的延长，Applied Therapeutics敦促股东投标股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APLT":0.9,"NDAQ":0.9},"content_text":"Applied Therapeutics Urges Shareholders to Tender Shares as Cycle Group Acquisition Offer Extended\n    \n\n        Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, has provided an update on its pending acquisition by Cycle Group Holdings Limited, a UK-based company specializing in rare genetic conditions. The company confirmed that the offer period for Cycle's subsidiary, AT2B, Inc., to purchase Applied Therapeutics shares has been extended. Applied Therapeutics reiterated that, after considering alternative strategic options and not receiving any competing proposals since the agreement was signed on December 11, 2025, the transaction with Cycle remains the best available option for maximizing stockholder value. The company also noted that if the transaction is not completed, the share price could decline, especially if current trading levels reflect expectations that the deal will close. This update was disclosed in a letter to stockholders from Applied Therapeutics.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Applied Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9645308-en) on January 29, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2607508084","isCrawlerRequest":true}